NCT04528706 - A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Cerebral Adrenoleukodystrophy

Interventions

DRUG

MIN-102

Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.

Trial Locations (5)

B16641NZ

Hernan Amartino, Bueno Aires

Unknown

CHU Kremlin Bicêtre, Paris

Universitätsmedizin Göttingen Georg-August-Universität, Göttingen

Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Kinder- und Jugendmedizin, Hamburg

Hospital Sant Joan de Déu, Barcelona